Edge Therapeutics Reports Fourth Quarter and Full-Year 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/30/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
Leerink Partners Cuts Price Target on Edge Therapeutics (EDGE) Following 4Q Results
March 8, 2016 1:51 PM ESTLeerink Partners maintained an Outperform rating on Edge Therapeutics (NASDAQ: EDGE), and cut the price target to $24.00 (from $27.00), following the company's 4Q. EDGE reported a net loss and EPS of $8.1M and ($0.30), which was largely in-line with Leerink's estimates of $7.9M and ($0.28).
Analyst... More
Edge Therapeutics (EDGE) Tops Q4 EPS by 2c
March 8, 2016 7:06 AM ESTEdge Therapeutics (NASDAQ: EDGE) reported Q4 EPS of ($0.30), $0.02 better than the analyst estimate of ($0.32).
For earnings history and earnings-related data on Edge Therapeutics (EDGE) click here.
... More